GlassScriptPhysician profile
Edward Prior
NPI 1336130293
$15,399.09
in general payments reported to CMS, 2019-2025
38 companies · $3,057 in 2025
The $3,057 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,113 · 2020: $998 · 2021: $2,539 · 2022: $1,746 · 2023: $2,885 · 2024: $2,061 · 2025: $3,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,983 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,982.71 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,211.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,207.41 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,383.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $1,283.10 | 2019-2024 | Verquvo, Steglatro, Belsomra |
| Lilly USA, LLC | $1,229.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $904.09 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $731.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.60 | 2019-2022 | |
| Pfizer INC. | $539.04 | 2019-2025 | |
| Allergan, INC. | $506.56 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.61 | 2019-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $338.64 | 2024-2025 | Auvelity, Symbravo |
| Sunovion Pharmaceuticals INC. | $251.82 | 2019-2022 | |
| Exact Sciences Corporation | $242.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $191.51 | 2022-2025 | Repatha, Repatha, Otezla |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Prior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.